Tag: DOAC
-
Stopping DOACs After AF Ablation: OCEAN Trial Findings
New Evidence Suggests DOACs May Be Stopped After Successful AF Ablation in Low-Risk Patients A new analysis from the OCEAN trial presents a provocative finding for clinicians and patients managing atrial fibrillation (AF): for low-risk individuals who have undergone successful AF ablation, continuing oral anticoagulants (DOACs) may not offer a clear advantage in preventing stroke…
-
DOAC Outcomes in NVAF Linked to Echocardiographic Hemodynamics
Overview: DOACs, NVAF, and the role of cardiac hemodynamics Non-valvular atrial fibrillation (NVAF) requires careful stroke prevention, with direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran replacing warfarin in many patients. While DOACs have demonstrated non-inferiority to warfarin in large trials, real-world data reveal nuances in bleeding and stroke risk that may hinge…
-
Echocardiographic Hemodynamics Reveal DOAC-Specific Bleeding and Stroke Differences in Non-Valvular Afib
Background: DOACs, NVAF, and the bleeding-stroke balance Atrial fibrillation (AF) and atrial flutter (AFL) elevate stroke risk, driving the widespread use of oral anticoagulants. Direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, and edoxaban—offer non-inferiority to warfarin with distinct bleeding profiles. In real-world practice, apixaban often shows the lowest overall bleeding, particularly GI bleeding, while rivaroxaban and…
-
Common Pitfalls of Polypharmacy in Heart Failure
What polypharmacy means for heart failure Polypharmacy, or taking multiple medications, is common among people living with heart failure. While many drugs are essential to manage symptoms and prevent progression, a heavy or uncoordinated medication load can introduce interactions and adverse effects that worsen outcomes. Recent evidence suggests that polypharmacy is significantly associated with higher…